This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results benefit from growth in Discover & Analytics Solutions segment. However, forex remains a woe.
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
Incyte (INCY) Misses Q1 Earnings Estimates, Beats on Revenues
by Zacks Equity Research
Incyte (INCY) misses on first-quarter earnings due to an upfront payment made in March related to a collaboration agreement. Sales beat on strong Jakafi growth.
Henry Schein (HSIC) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Henry Schein (HSIC) sees dismal performance by Dental arm in Q1 due to disruptions resulting from the coronavirus pandemic.
Tandem Diabetes (TNDM) Q1 Loss Widens, Revenues Top Estimates
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic pump sales and the company's expansion in international markets boost the top line.
Teleflex (TFX) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Teleflex's (TFX) first-quarter 2020 results reflect sales growth across few major segments despite the coronavirus pandemic.
Hill-Rom's (HRC) Q2 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Hill-Rom (HRC) benefits from increased product demand due to the coronavirus outbreak.
Syneos Health (SYNH) Tops Q1 Earnings Estimates, Margins Down
by Zacks Equity Research
The coronavirus impact results in inaccessibility of several of Syneos Health's (SYNH) clinical trial sites.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Illumina (ILMN) Beats Q1 Earnings Estimates, Withdraws View
by Zacks Equity Research
Illumina (ILMN) exhibits robust growth in the first quarter of 2020 fueled by strong performance of the sequencing consumable subsegment despite the coronavirus pandemic.
Hologic (HOLX) Beats Q2 Earnings Estimates, Withdraws View
by Zacks Equity Research
Hologic (HOLX) exhibits robust segmental growth in second-quarter fiscal 2020, fueled by strong performance by the Diagnostics segment amid the coronavirus pandemic.
Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat
by Ritujay Ghosh
A large number of biotech companies have been working on developing drugs and vaccine for the novel coronavirus that has infected more than 3,100,000 and claimed 227,000 lives.
United Therapeutics (UTHR) Down Despite Q1 Earnings Beat
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates for both earnings and sales in first quarter. It expects a reduction in new patient starts in the future quarters. Stock down.
Eli Lilly and Company, PVH, Alphabet, Starbucks and Ford Motor highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Eli Lilly and Company, PVH, Alphabet, Starbucks and Ford Motor highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Eli Lilly (LLY)
by Tracey Ryniec
Double digit earnings growth expected in 2020 and it pays a dividend too.
Top Stock Research Reports for Cisco, Abbott, NextEra & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Cisco (CSCO), Abbott Laboratories (ABT) and NextEra Energy (NEE).
Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Merck (MRK) beats estimates for earnings as well as for sales in first-quarter 2019. The company lowers its sales and earnings guidance to include impact of COVID-19. Shares down.
Big Drug Stock Q1 Earnings Due on Apr 28: MRK, PFE and NVS
by Kinjel Shah
Let us take a look at three big drug companies due to release their first-quarter financial results on Apr 28.
Bayer (BAYRY) Q1 Earnings Beat Estimates, Sales Rise Y/Y
by Zacks Equity Research
Bayer (BAYRY) beats earnings estimates for the first quarter of 2019.
Company News for Apr 24, 2020
by Zacks Equity Research
Companies In The News Are: LLY, SAVA, FLR, LYTS
Will Eli Lilly and Company Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Eli Lilly and Company
Pharma Stock Roundup: Q1 Earnings of LLY, Coronavirus Update from PFE, NVS, AZN
by Kinjel Shah
Eli Lilly (LLY) announces Q1 results. Pfizer (PFE) and Novartis (NVS) provide update on their studies/plans to make coronavirus treatments or vaccines.
Eli Lilly (LLY) Is Up 7.93% in One Week: What You Should Know
by Zacks Equity Research
Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Jobless Claims Still High but Coming Down, Plus More Q1 Results
by Mark Vickery
4.427 million new jobless claims were made in the past week, bringing the total of the past 5 weeks of new claims data to north of 26 million workers in the U.S.
Lilly (LLY) Q1 Earnings Beat, Coronavirus May Mar Profits
by Zacks Equity Research
Eli Lilly (LLY) beat estimates for both earnings and sales in the first quarter of 2020. However, the company warns that coronavirus-related uncertainty may hurt financial results in 2020 and beyond.